• Publications
  • Influence
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
TLDR
A database containing information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquantitative prediction of the magnitude of potential interactions with drugs under development. Expand
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
TLDR
The large increase in the plasma concentrations of other protease inhibitors when coadministered with ritonavir forms the basis of rational dual protease inhibitor regimens, providing patients with 2 potent drugs at significantly reduced doses and less frequent dosage intervals. Expand
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
TLDR
The liquid coformulation of lopinavir/ritonavir demonstrated durable antiviral activity and was safe and well-tolerated after 48 weeks of treatment in HIV-infected children. Expand
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
TLDR
The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations. Expand
Protein binding in antiretroviral therapies.
TLDR
In June 2002, a panel of experts assembled by the Forum for Collaborative HIV Research met in Washington, DC, to discuss the basic principles of protein binding and how changes in binding can impact on drug PKs and drug exposure in vivo, and the evidence that measuring unbound concentrations of ARV drugs in the plasma of patients gives more meaningful information than total drug concentration. Expand
Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir
TLDR
The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir and a Phase III study in HIV-HCV coinfection has commenced using the described dose modifications. Expand
Safety and exposure of once‐daily ritonavir‐boosted atazanavir in HIV‐infected pregnant women
TLDR
This study assessed the safety, efficacy and appropriate dosing regimen for ritonavir (RTV)‐boosted atazanavir in HIV‐1‐infected pregnant women. Expand
Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers
TLDR
Adjusted-dose regimens of lopinavir-ritonavir in combination with therapeutic drug monitoring and monitoring of liver function may allow concomitant use of rifampin. Expand
Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction
TLDR
Concomitant LPV/RTV and PHT use results in a 2-way drug interaction, and Phenytoin appears to increase LPV clearance via CYP3A4 induction, which is not offset by the presence of low-dose RTV. Expand
Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
TLDR
Dasatinib exposure is unchanged when antacid (Maalox) is administered 2 hours before dasatinIB; but when the antacid is coadministered with d asatinib, dasATI exposure is reduced by ∼55% to 58%. Expand
...
1
2
3
4
5
...